048410 — Hyundai Bioscience Co Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Hyundai Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-8,607	-20,051	-15,807	-14,499	-6,930
Depreciation
Amortisation
Non-Cash Items	4,520	10,974	-4,516	5,252	8,094
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	7,811	5,835	1,997	1,804	459
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	7,502	-538	-16,544	-6,008	2,257
Capital Expenditures	-25,204	-3,762	-1,544	-588	-2,170
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1,626	-8,597	10,061	5,765	-17,571
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-26,831	-12,359	8,518	5,177	-19,740
Financing Cash Flow Items	-867	-210	-229	-289	-435
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	32,951	2,994	1,673	-58	19,190
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	13,660	-10,026	-6,456	-921	1,845